Pfizer Boosts Forecast for Vaccine Sales to $33.5 Billion
Comment of the Day

July 28 2021

Commentary by Eoin Treacy

Pfizer Boosts Forecast for Vaccine Sales to $33.5 Billion

This article from Bloomberg may be of interest to subscribers. Here is a section:

 

A resurgence of virus infections thanks to the delta variant is likely to mean sustained demand for vaccines around the world. Further, it is widely expected that many people could require booster shoots to bolster the immunity gained in the initial round of immunizations.

Pfizer said in a presentation accompanying its earnings release that emerging real-world data “suggests immunity against infection and symptomatic disease may wane,” underscoring the need for boosters.

The company said regulators will determine “whether, and which, populations to recommend booster,” and that they will likely first focus on those with compromised immune systems and older adults.

Eoin Treacy's view

The ideal business model for any pharmaceutical company is to develop a treatment for an unmet but dire chronic condition. Diabetes is the perfect example. There is no cure and treatments are both necessary and tend to increase in magnitude as the disease progresses. Each patient represents a growing cashflow for as long as they live following a diagnosis. Viagra was also a blockbuster because it catered to an unmet need but did not cure it. 

Click HERE to subscribe to Fuller Treacy Money Back to top